ClinicalTrials.gg
WithdrawnNCT05609812COMPASSUpdated May 23, 2025

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

A Phase 3 interventional study of Atacicept and Placebo in Lupus Nephritis (LN), sponsored by Vera Therapeutics, Inc.. Withdrawn at 33 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Vera Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
91st of 100
0 · median 50
Started
2022
with 7 others
Phase 3
16 of 114
2 open now
Registered
65th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 91st largest by enrollment of the 100 interventional ones that give a count, is one of 8 that started in 2022, is one of 16 in phase 3, and was the 65th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.

Read the detailed description

The study will assess atacicept vs. placebo on the impact of renal function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period.

03

Conditions studied

  • Lupus Nephritis (LN)

Keywords

  • Systemic Lupus erythematosus (SLE)
  • estimated glomerular filtration rate (eGFR)
  • protenuria
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or Female at least 18 years of age at time of signing consent
  2. Must have the ability to understand and sign and date a written form
  3. Diagnosis of SLE
  4. - Proven Active LN
  5. Requires high-dose and therapy for the treatment of active LN
  6. Subject is willing to take oral MMF for the duration of the study

Key Exclusion Criteria:

  1. of ≤30 mL/min/1.73 m2.
  2. Sclerosis in 50% of glomeruli on renal biopsy.
  3. Evidence of rapidly progressive glomerulonephritis.
  4. Currently requiring renal dialysis or expected to require dialysis during the study.
  5. Serum igG \<7 g/L
  6. Active infection or high infectious risk
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Atacicept Dose

    Atacicept Dose once weekly subcutaneous (SC) Injection

    Drug: Atacicept

  • Placebo comparator
    Placebo to match Atacicept

    Placebo to match Atacicept once weekly subcutaneous (SC) injection

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Renal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%

    Time frame: Week 52

Secondary outcomes

  1. Renal Response with alternative success criteria

    Time frame: Weeks 52 and 104

  2. Time to UPCR of≤0.5 mg/mg

    Time frame: Week 52

  3. Renal Response at Week 104

    Time frame: Week 104

  4. Time to Death or Renal-Related Event

    Time frame: Week 104

07

Study locations

33 sites
  • Vera Site # 0139
    Huntsville, Alabama 35805, United States
  • Vera Site # 0138
    La Jolla, California 92037, United States
  • Vera Site # 0127
    La Palma, California 90623, United States
  • Vera Site # 0129
    Long Beach, California 90822, United States
  • Vera Site # 0135
    Northridge, California 91324, United States
  • Vera Site # 0136
    Northridge, California 91324, United States
  • Vera Site # 0130
    Santa Clarita, California 91321, United States
  • Vera Site # 0131
    Torrance, California 90502, United States
  • Vera Site # 0143
    New Haven, Connecticut 06520, United States
  • Vera Site # 0140
    Gainesville, Florida 32610, United States
  • Vera Site # 0128
    Miami, Florida 33125, United States
  • Vera Site # 0134
    Atlanta, Georgia 30309, United States
  • Vera Site # 0137
    Augusta, Georgia 30912, United States
  • Vera Site # 0144
    Augusta, Georgia 30912, United States
  • Vera Site # 0147
    Lawrenceville, Georgia 30046, United States
  • Vera Site # 0109
    Chicago, Illinois 60611, United States
  • Vera Site # 0133
    Las Vegas, Nevada 89106, United States
  • Vera Site # 0149
    Summit, New Jersey 07901, United States
  • Vera Site # 0146
    New York, New York 10016, United States
  • Vera Site # 0142
    New York, New York 10039, United States
  • Vera Site # 0148
    Cleveland, Ohio 44109, United States
  • Vera Site # 0145
    Columbus, Ohio 43210, United States
  • Vera SIte # 0132
    Jackson, Tennessee 38305, United States
  • Vera Site # 0125
    Dallas, Texas 75231, United States
  • Vera Site # 0126
    Dallas, Texas 75231, United States
  • Vera Site # 0122
    El Paso, Texas 79925, United States
  • Vera Site # 0141
    Coto Laurel, 00780, Puerto Rico
  • Vera Site # 0348
    Barcelona, 08035, Spain
  • Vera Site # 0347
    Barcelona, 08036, Spain
  • Vera Site # 0349
    Coruna, 15006, Spain
  • Vera Site #0351
    Santander, 39008, Spain
  • Vera Site # 0350
    Sevilla, 41013, Spain
  • Vera Site # 0346
    Valencia, 4601, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Mar 2026, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Nov 8, 2022
StartActual
Nov 2, 2022
Primary completionEst.
Mar 15, 2026
CompletionEst.
Dec 15, 2028
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05609812
Lead sponsor
Vera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Nov 2, 2022
Primary completion
Mar 15, 2026 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
May 23, 2025

Study contacts

Joanne Curley
study director · Chief Development Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion